Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 4/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.57 |
| ▸ | GRM8 | O00222 | 1/20 | 0.57 |
| ▸ | GRM6 | O15303 | 1/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.57 |
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.57 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.57 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710756 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL27956852 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL8382463 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL435318 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL7923681 | 1.00 | FOLH1 (0.62) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL28486006 | 0.98 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL28486008 | 0.98 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL22111146 | 0.96 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL20739235 | 0.96 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 | |
| SCHEMBL20739236 | 0.96 | FOLH1 (0.58) | FOLH1NAALAD2RIMKLADPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20230410977-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES | 2023-12-21 | — | — | US | claimed |
| CN-114965800-A | Renal clear cell carcinoma biomarker and application thereof in early screening | 山西医科大学 | 2022-08-30 | — | — | CN | claimed |
| WO-2022140565-A1 | METHODS AND MATERIALS FOR ASSESSING RADIATION EXPOSURE | NUTECH VENTURES (US) | 2022-06-30 | — | — | WO | claimed |
| US-20160282351-A1 | SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS | SALIVATECH CO., LTD. (JP) | 2016-09-29 | — | — | US | claimed |
| EP-3064940-A1 | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | Salivatech Co., Ltd. (JP) | 2016-09-07 | — | — | EP | claimed |
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| WO-2012010851-A1 | CAPILLARY ELECTROPHORESIS OF CARBOHYDRATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-01-26 | — | — | WO | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-3806661-B1 | USE OF ANTAGONISTS OF T2R54 | FIRMENICH INCORPORATED (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4566459-A2 | ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF | Firmenich Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | FIRMENICH INCORPORATED (US) | 2025-05-13 | — | — | US | disclosed |
| WO-2025038709-A1 | METHODS OF FORMING RADIOPAQUE PEPTIDES AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-0826766-A2 | Wash composition | Ajinomoto Co., Inc. (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5356805-A | Gamma-polyglutamate hydrolase | MEIJI SEIKA KAISHA, LTD. (JP) | 1994-10-18 | — | — | US | disclosed |
| EP-0559175-A2 | gamma-Polyglutamate hydrolase and process for producing same | MEIJI SEIKA KAISHA LTD. (JP) | 1993-09-08 | — | — | EP | disclosed |
| EP-0232717-B1 | ANTIBODY SPECIFIC TO LOW-MOLECULAR WEIGHT SUBSTANCE AND METHOD OF PRODUCING THE SAME BY USING COLLOIDAL METAL PARTICLES AS CARRIER | Sadao Shiosaka (CA) | 1993-04-14 | — | — | EP | disclosed |
| US-5112606-A | METHOD OF PRODUCING ANTIBODIES USING COLLOIDAL METAL AS CARRIER | SHIOSAKA SADAO (CA) | 1992-05-12 | — | — | US | disclosed |
| EP-0232717-A2 | Antibody specific to low-molecular weight substance and method of producing the same by using colloidal metal particles as carrier | Sadao Shiosaka (CA) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295396-B2 | Antagonists of T2R54 and compositions and uses thereof | TAS2R50, TAS2R30, TAS2R60 | FOLH1 1173/4885NAALAD2 1629/4885RIMKLA 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.